Related Experiment Video
Updated: Aug 2, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Cancer research 2001: drug resistance, new targets and drug combinations
H J Broxterman1, N Georgopapadakou
1Department of Medical Oncology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands. H.Broxterman@vumc.nl
Abstract:
The development of new anticancer drugs and the identification of novel targets represent major focus areas for pharmaceutical and biotech companies, universities and research institutes worldwide. The 92nd Annual Meeting of the American Association for Cancer Research (AACR) provided a glimpse of the latest developments in the cancer field. We highlight here presentations on resistance mechanisms (efflux, target modulation), new targets and drugs in development (topoisomerase, angiogenesis, cell cycle inhibitors) and new molecular technologies. The emergence of technologies for concurrently screening for expression of thousands of genes, has provided a new approach for the identification of molecular targets and mechanisms of both action and resistance of new compounds. The importance of inhibiting multiple targets simultaneously was brought up in several presentations.
Insights
Researchers are exploring new anticancer drugs and targets, focusing on resistance mechanisms and novel molecular technologies. Advances in gene screening enable better identification of drug targets and resistance pathways.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- The development of novel anticancer therapeutics and drug targets is a critical area of research for academic institutions and the pharmaceutical industry.
- The 92nd Annual Meeting of the American Association for Cancer Research (AACR) showcased recent advancements in cancer research.
Framework:
- This summary highlights key themes from the AACR meeting, including drug resistance mechanisms, emerging drug targets, and innovative molecular technologies.
- Focus areas include efflux and target modulation for resistance, and topoisomerase, angiogenesis, and cell cycle inhibitors as new therapeutic strategies.
Implementation:
- High-throughput screening technologies, such as those for concurrent gene expression analysis, are revolutionizing the identification of molecular targets.
- These technologies facilitate the understanding of drug mechanisms of action and resistance.
Implications:
- Simultaneous inhibition of multiple targets is emerging as a crucial strategy in cancer treatment, as discussed in several presentations.
- These advancements promise to accelerate the discovery and development of more effective cancer drugs.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...